Technology Listings

7,8-Dihydroxyflavone Derivatives for Treating Neurological and Neurodegenerative Diseases


Family of small molecule 7,8-dihydroxyflavones that act as TrkB agonists, including a prodrug, for treating a number of neurological conditions and diseases.

Key Benefits
  • Has antidepressant-like properties, improves cognitive function, and promotes neuronal survival in animal models of neurological diseases.
  • Whereas current anti-depressant and anti-anxiety medications take 1-2 months to take effect, and frequently produce very harsh side effects, 7,8-dihydroxyflavone is a potent anti-depressant that demonstrates therapeutic efficacy within a few days.
  • Substantial patent portfolio with large number of protected derivatives.
  • May be effective against several neurological disease indications.
Market Summary

Brain-derived neurotrophic factor (BDNF), a ligand that activates the TrkB receptor, is of interest as a therapeutic target due to its neuroprotective properties. Treatment with BDNF, however, is not an option due to poor efficiency, bioavailability, adverse side effects, and inability to cross the blood brain barrier. Because dysregulation of BDNF and TrkB receptor activation is implicated in a variety of neurological diseases, the impact of a TrkB agonist could prove to be quite profound. Some disorders that may benefit from this therapeutic include Parkinson’s disease, Alzheimer’s disease, stroke, Rett Syndrome, Huntington’s disease, Amyolateral Sclerosis, glaucoma, macular degeneration, anxiety, and depression.

Technical Summary

Researchers at Emory have identified a TrkB agonist, 7,8-dihydroxyflavone (7,8-DHF), that has improved activity, bioavailability, and fewer deleterious side effects. Moreover, Dr. Ye and colleagues are doing further structure activity relationships assays to identify additional modifications that could further improve upon this small molecule therapeutic. Treatment with 7,8-DHF improves Parkinsonian symptoms in animal models, reduces anxiety, increases synaptic plasticity, and promotes neuronal survival. Through a structure-activity relationship study, a derivative of 7,8-DHF was found to have higher and more prolonged TrkB agonistic activity than 7,8-DHF in vitro. There is currently a lead compound which has anti-apoptotic activity.

View our featured innovation.

Developmental Stage

This small molecule program has a lead candidate and additional work is ongoing.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Nationalized PCT - Foreign India 1201/DELNP/2011   7/23/2009   2/18/2011 Pending
Nationalized PCT - Foreign EP 09801005.1   1/28/2011   7/23/2029 Pending
Nationalized PCT - United States United States 13/055,861 9,895,344 2/23/2011 2/20/2018 4/2/2031 Issued
Nationalized PCT - Foreign China 200980134395.1   3/2/2011   7/23/2029 Pending
Nationalized PCT - United States United States 13/643,769 9,029,561 10/26/2012 5/12/2015 7/3/2031 Issued
Nationalized PCT - Foreign EP 11793086.7 2579870 11/16/2012 2/14/2018 6/8/2031 Issued
EP Registered Country United Kingdom 11793086.7 2579870 11/16/2012   6/8/2031 Issued
Nationalized PCT - Foreign Australia 2011264917 2011264917 11/29/2012 11/19/2015   Pending
Nationalized PCT - Foreign China 201180027364.3 ZL201180027364.3 12/3/2012 1/27/2016 6/7/2031 Issued
Nationalized PCT - Foreign China 2013800385775 ZL2013800385775 7/25/2013 7/14/2017 7/25/2033 Issued
Nationalized PCT - United States United States 14/410,756 9,593,125 12/23/2014 3/14/2017 7/25/2033 Issued
Nationalized PCT - Foreign EP 13822110.6   1/7/2015   7/25/2033 Pending
Divisional United States 14/639,343 9,504,674 3/5/2015 11/29/2016 6/8/2031 Issued
Divisional China 201610018368.X   1/12/2016     Abandoned
Divisional United States 15/416,964 10,010,526 1/26/2017 7/3/2018 7/25/2033 Issued
Tech ID: NCS.01
Published: 10/18/2016

Sarah Wilkening
Licensing Associate
Emory University
(404) 727-1969

Keqiang Ye

Small Molecule